{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:47Z","timestamp":1791276467821,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/inf.0b013e31824acc33","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T12:15:32Z","timestamp":1328616932000},"page":"632-635","source":"Crossref","is-referenced-by-count":40,"title":["Therapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age"],"prefix":"10.1097","volume":"31","author":[{"given":"Elizabeth H.","family":"Doby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R2-22-20210202","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-22-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children.","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-22-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R5-22-20210202","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"R6-22-20210202","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy.","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R7-22-20210202","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit.","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R8-22-20210202","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokineticpharmacodynamic profile of voriconazole.","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R10-22-20210202","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-22-20210202","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases.","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"R12-22-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","article-title":"Voriconazole plasma levels in children are highly variable.","volume":"30","author":"Spriet","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R13-22-20210202","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R14-22-20210202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/FTD.0b013e3182241b2b","article-title":"Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.","volume":"33","author":"Gerin","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R15-22-20210202","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0b013e318204d227","article-title":"Impact of therapeutic drug monitoring of voriconazole in a pediatric population.","volume":"30","author":"Bruggemann","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R16-22-20210202","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.jp.7211532","article-title":"Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.","volume":"26","author":"Frankenbusch","year":"2006","journal-title":"J Perinatol"},{"key":"R17-22-20210202","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.inf.0000095167.38306.76","article-title":"Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection.","volume":"22","author":"Maples","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R18-22-20210202","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1592\/phco.2005.25.6.893","article-title":"Intravenous voriconazole therapy in a preterm infant.","volume":"25","author":"Muldrew","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R19-22-20210202","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.inf.0000258698.98370.89","article-title":"Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.","volume":"26","author":"Santos","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R20-22-20210202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R21-22-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-010-0811-8","article-title":"Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).","volume":"66","author":"Ward","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-22-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/dmd.109.029769","article-title":"In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.","volume":"38","author":"Yanni","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R24-22-20210202","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent.","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e31824acc33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:30:59Z","timestamp":1620955859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201206000-00022"}},"subtitle":["A Case Report and Summary of Voriconazole Concentrations for Ten Children"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31824acc33","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}